Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology - United Kingdom
doi 10.1002/hon.78_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

British Journal of Haematology
Hematology
2016English

Pembrolizumab With Rchop in Previously Untreated Diffuse Large B-Cell and Grade 3b Follicular Lymphoma: Final Results of a Phase I Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Combination of Chidamide With Choep Regimen in Previously Untreated Patients With Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ncri Petrea Trial: A Phase 3 Evaluation of Pet-Guided, Response-Adapted Therapy in Patients With Previously Untreated, Advanced-Stage, High-Tumour-Burden Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy